Alirocumab versus usual lipid ‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

ConclusionsIn individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority in non‐HDL‐C reduction vs UC and was generally well tolerated.

Source: Diabetes, Obesity and Metabolism - February 1, 2018 Category: Endocrinology Authors: Kausik K. Ray, Lawrence A. Leiter, Dirk M üller‐Wieland, Bertrand Cariou, Helen M. Colhoun, Robert R. Henry, Francisco J. Tinahones, Maja Bujas‐Bobanovic, Catherine Domenger, Alexia Letierce, Rita Samuel, Stefano Del Prato Tags: ORIGINAL ARTICLE Source Type: research